Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML

Blood
Annahita SallmyrFeyruz V Rassool

Abstract

Activating mutations of the FMS-like tyrosine kinase-3 (FLT3) receptor occur in approximately 30% of acute myeloid leukemia (AML) patients and, at least for internal tandem duplication (ITD) mutations, are associated with poor prognosis. FLT3 mutations trigger downstream signaling pathways including RAS-MAP/AKT kinases and signal transducer and activator of transcription-5 (STAT5). We find that FLT3/ITD mutations start a cycle of genomic instability whereby increased reactive oxygen species (ROS) production leads to increased DNA double-strand breaks (DSBs) and repair errors that may explain aggressive AML in FLT3/ITD patients. Cell lines transfected with FLT3/ITD and FLT3/ITD-positive AML cell lines and primary cells demonstrate increased ROS. Increased ROS levels appear to be produced via STAT5 signaling and activation of RAC1, an essential component of ROS-producing NADPH oxidases. A direct association of RAC1-GTP binding to phosphorylated STAT5 (pSTAT5) provides a possible mechanism for ROS generation. A FLT3 inhibitor blocked increased ROS in FLT3/ITD cells resulting in decreased DSB and increased repair efficiency and fidelity. Our study suggests that the aggressiveness of the disease and poor prognosis of AML patients wi...Continue Reading

References

Jan 18, 1994·Proceedings of the National Academy of Sciences of the United States of America·D SmallA M Gewirtz
Jun 1, 1995·Differentiation; Research in Biological Diversity·O deLapeyrièreD Birnbaum
Jun 1, 1994·Chemico-biological Interactions·M MeyerP A Baeuerle
Jan 1, 1996·Free Radical Biology & Medicine·Y Sun, L W Oberley
Mar 14, 1997·Science·K IraniP J Goldschmidt-Clermont
Feb 1, 1997·Environmental Health Perspectives·V Vallyathan, X Shi
Jun 30, 1998·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·X ShiV Vallyathan
Oct 28, 1998·Environmental Health Perspectives·V VallyathanV Castranova
Jun 2, 2000·The Journal of Biological Chemistry·M SattlerJ D Griffin
Aug 16, 2000·American Journal of Physiology. Cell Physiology·S WangX Shi
Nov 25, 2000·Molecular Cell·K LapougeK Rittinger
Jun 4, 2002·Current Opinion in Hematology·D Gary Gilliland, James D Griffin
Jun 11, 2002·Biochemical and Biophysical Research Communications·Laurent DejeanMichel Rigoulet
Aug 5, 2003·Molecular and Cellular Biology·Kai RothkammMarkus Löbrich
Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Sep 13, 2003·Leukemia·M Levis, D Small
Dec 4, 2003·Expert Opinion on Investigational Drugs·Mark Levis, Donald Small
Feb 6, 2004·Seminars in Cancer Biology·Alison M JohnRose Ann Padua
Feb 20, 2004·Molecular and Cellular Biochemistry·Suwei WangXianglin Shi
Jun 11, 2004·Seminars in Hematology·Pierre Fenaux
Dec 22, 2004·The Journal of Biological Chemistry·Yuichi SekineTadashi Matsuda
Mar 22, 2005·The International Journal of Biochemistry & Cell Biology·Ana MarkovicRichard B Lock
Feb 17, 2006·Molecular Biology of the Cell·Huibin Yang, Raymond R Mattingly
Apr 26, 2006·The Journal of Biological Chemistry·Guangjie ChengJ David Lambeth
Jun 10, 2006·The Journal of Biological Chemistry·Kei MiyanoHideki Sumimoto
Jul 28, 2006·British Journal of Haematology·Kyu-Tae KimDonald Small

❮ Previous
Next ❯

Citations

Apr 30, 2013·Apoptosis : an International Journal on Programmed Cell Death·C HinterleitnerG Fritz
Jun 12, 2012·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Yin XiaoLingbo Liu
May 30, 2008·Frontiers in Bioscience : a Journal and Virtual Library·Jan-Wilhelm KornfeldRichard Moriggl
Sep 10, 2008·Molecular and Cellular Biology·Albertus T J WierengaJan Jacob Schuringa
Nov 21, 2008·Antioxidants & Redox Signaling·Joya Chandra
Jan 10, 2009·The Journal of Biological Chemistry·Yin GaoJoya Chandra
Oct 7, 2011·Cell Death & Disease·D R Gough, T G Cotter
Feb 11, 2009·Blood·Dirk Schmidt-ArrasFrank-D Böhmer
Aug 21, 2012·Antioxidants & Redox Signaling·Mary E IrwinJoya Chandra
Jul 14, 2010·Oncogene·E WeisbergJ D Griffin
Sep 27, 2012·Free Radical Research·Aoife Corcoran, Thomas G Cotter
Jan 1, 2014·Journal of Clinical Medicine·Caroline Benedicte Nitter EngenBjørn Tore Gjertsen
Jan 27, 2015·International Journal of Molecular Sciences·Christine RichardsonC Greer Vestal
Nov 19, 2010·Expert Review of Hematology·Anna MartnerKristoffer Hellstrand
Oct 1, 2015·Chembiochem : a European Journal of Chemical Biology·Fathima Shazna ThowfeikEdward Joseph Merino
Apr 22, 2011·Critical Reviews in Oncology/hematology·José L SardinaAngel Hernández-Hernández
Feb 4, 2011·Experimental Hematology·Timothy S PardeeScott W Lowe
Mar 26, 2016·Frontiers in Immunology·Nicolas DulphyAntoine Toubert
Jun 12, 2012·The FEBS Journal·Frank BöhmerJeroen den Hertog
Mar 1, 2016·Experimental Hematology·Ya-Huei KuoGuerry J Cook
Apr 11, 2014·BioMed Research International·Marianna GuidaAnto De Pol
Mar 13, 2014·DNA Repair·Philippe FritPatrick Calsou

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.